3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
18
Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Sarcoma
6
Prostatic Neoplasms
6
Fanconi Anemia, Complementation Group D1
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Stomach Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Mesothelioma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumors
2
Wilms Tumor
1
Interventions
Nivolumab
13
Surveys and Questionnaires
6
Ipilimumab
6
linrodostat
5
Standard of Care
5
Paclitaxel
5
Bevacizumab
5
Sirolimus
4
Pemetrexed
4
Interviews as Topic
4
Gemcitabine
4
Docetaxel
4
ARRY-334543
4
temsirolimus
3
relatlimab
3
Erlotinib Hydrochloride
3
Cetuximab
3
Carboplatin
3
regorafenib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Trastuzumab
2
Sorafenib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Dasatinib
2
Cyclophosphamide
2
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Cancer
×
olaparib
×
Clear all
NCT02338622
2024-09-26
ComPAKT
Royal Marsden NHS Foundation Trust
Phase 1
Completed
60 enrolled